Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
DIN 02474026: Mezera
Raw flags: sec3=Y
Item: 564000137; group id 672; item number 1667; lccId None; manufacturer id AVP
Source form: 14 Actuation-Foam Enema Canister Pk; strength: 1g/Actuation
Recorded listing: General benefit
Source prices (unrounded): $103.8600; ministry $103.8600
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474026
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96403
Shortage status: resolved shortage (ended March 26, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474026
Shortage record checked October 6, 2026
Mezera · DIN 02545012 · 1 g · DR tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02545012
Manufacturer: Avir Pharma Inc.; listing date 2025-04-30
Health Canada: Marketed since 2024-07-26 · brand MEZERA · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 1 G · company Avir pharma inc. · schedule Prescription
DIN 02545012: Mezera
Raw flags: sec3=Y
Item: 564000145; group id 672; item number 1670; lccId None; manufacturer id AVP
Source form: DR Tab; strength: 1g
Recorded listing: General benefit
Source prices (unrounded): $1.3011; ministry $1.3011
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02545012
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103363
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02545012
Shortage record checked October 6, 2026
Pentasa · DIN 02399466 · 1 g · extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02399466
Manufacturer: Ferring Inc.; listing date 2013-11-28
Health Canada: Marketed since 2013-03-12 · brand PENTASA · ATC A07EC02 MESALAZINE · form Tablet (extended-release) · route Oral · ingredients MESALAZINE 1 G · company Ferring inc · schedule Prescription
DIN 02399466: Pentasa
Raw flags: sec3=Y
Item: 564000127; group id 672; item number 1675; lccId None; manufacturer id FEI
Source form: ER Tab; strength: 1g
Recorded listing: General benefit
Source prices (unrounded): $1.5540; ministry $1.5540
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02399466
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88434
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399466
Shortage record checked October 6, 2026
Pentasa · DIN 02153521 · 1 g/100 mL · Enema
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153521
Manufacturer: Ferring Inc.; listing date 1996-12-19
Health Canada: Marketed since 1999-11-09 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 1 G/100ML · company Ferring inc · schedule Prescription
DIN 02153521: Pentasa
Raw flags: sec3=Y
Item: 564000075; group id 672; item number 1672; lccId None; manufacturer id FEI
Source form: Enema; strength: 1g/100mL
Recorded listing: General benefit
Source prices (unrounded): $6.8600; ministry $6.8600
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02153521
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18496
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02153521
Shortage record checked October 6, 2026
Mezera · DIN 02474018 · 1 g · suppository
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02474018
Manufacturer: Avir Pharma Inc.; listing date 2019-08-30
Health Canada: Marketed since 2018-07-13 · brand MEZERA · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1 G · company Avir pharma inc. · schedule Prescription
DIN 02474018: Mezera
Raw flags: sec3=Y
Item: 564000136; group id 672; item number 1677; lccId None; manufacturer id AVP
Source form: Sup; strength: 1g
Recorded listing: General benefit
Source prices (unrounded): $1.9076; ministry $1.9076
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474018
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96402
Shortage status: resolved shortage (ended June 2, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474018
Shortage record checked October 6, 2026
Pentasa · DIN 02153564 · 1 g · suppository
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153564
Manufacturer: Ferring Inc.; listing date 1996-12-19
Health Canada: Marketed since 1999-11-09 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1 G · company Ferring inc · schedule Prescription
DIN 02153564: Pentasa
Raw flags: sec3=Y
Item: 564000074; group id 672; item number 1679; lccId None; manufacturer id FEI
Source form: Sup; strength: 1g
Recorded listing: General benefit
Source prices (unrounded): $2.7020; ministry $2.7020
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02153564
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18493
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02153564
Shortage record checked October 6, 2026
Mezavant · DIN 02297558 · 1.2 g · Delayed & extended release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Mezavant · DIN 02297558
Manufacturer: Takeda Canada Inc.; listing date 2009-04-01
Health Canada: Marketed since 2021-11-22 · brand MEZAVANT · ATC A07EC02 MESALAZINE · form Tablet (delayed- and extended-release) · route Oral · ingredients MESALAZINE 1.2 G · company Takeda canada inc · schedule Prescription
DIN 02297558: Mezavant
Raw flags: sec3=Y
Item: 564000107; group id 672; item number 1669; lccId None; manufacturer id TAK
Source form: Delayed & ER Tab; strength: 1.2g
Recorded listing: General benefit
Source prices (unrounded): $2.0520; ministry $2.0520
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297558
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78289
Shortage status: resolved shortage (ended July 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297558
Shortage record checked October 6, 2026
Pentasa · DIN 02153556 · 4 g/100 mL · Enema
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153556
Manufacturer: Ferring Inc.; listing date 1996-12-19
Health Canada: Marketed since 1999-11-08 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 4 G/100ML · company Ferring inc · schedule Prescription
DIN 02153556: Pentasa
Raw flags: sec3=Y
Item: 564000077; group id 672; item number 1673; lccId None; manufacturer id FEI
Source form: Enema; strength: 4g/100mL
Recorded listing: General benefit
Source prices (unrounded): $9.4700; ministry $9.4700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02153556
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18494
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02153556
Shortage record checked October 6, 2026
Salofalk · DIN 02112809 · 4 g · Rect suspension-Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112809
Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2024-06-12 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 4 G/60G · company Abbvie corporation · schedule Prescription
DIN 02112809: Salofalk
Raw flags: sec3=Y
Item: 564000034; group id 672; item number 1676; lccId None; manufacturer id BFI
Source form: Rect Susp-Pk; strength: 4g
Recorded listing: General benefit
Source prices (unrounded): $10.0389; ministry $10.0389
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02112809
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18509
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02112809
Shortage record checked October 6, 2026
Teva-5-ASA · DIN 02171929 · 400 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-5-ASA · DIN 02171929
Manufacturer: Teva Canada Limited; listing date 2008-12-23
Health Canada: Marketed since 2015-05-12 · brand TEVA-5 ASA · ATC A07EC02 MESALAZINE · form Tablet (enteric-coated) · route Oral · ingredients MESALAZINE 400 MG · company Teva canada limited · schedule Prescription
DIN 02171929: Teva-5-ASA
Raw flags: sec3=Y
Item: 564000030; group id 672; item number 1681; lccId None; manufacturer id TEV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.4758; ministry $0.4758
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02171929
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19524Interchangeable products
Asacol · DIN 01997580 · not recorded
Shortage status: resolved shortage (ended January 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171929
Shortage record checked October 6, 2026
Mezera · DIN 02524481 · 500 mg · DR tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02524481
Manufacturer: Avir Pharma Inc.; listing date 2024-01-31
Health Canada: Marketed since 2022-10-05 · brand MEZERA · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 500 MG · company Avir pharma inc. · schedule Prescription
DIN 02524481: Mezera
Raw flags: sec3=Y
Item: 564000139; group id 672; item number 1671; lccId None; manufacturer id AVP
Source form: DR Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6760; ministry $0.6760
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524481
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101350
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524481
Shortage record checked October 6, 2026
Pentasa · DIN 02099683 · 500 mg · Del-Release tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02099683
Manufacturer: Ferring Inc.; listing date 1996-10-01
Health Canada: Marketed since 1999-04-01 · brand PENTASA · ATC A07EC02 MESALAZINE · form Tablet (extended-release) · route Oral · ingredients MESALAZINE 500 MG · company Ferring inc · schedule Prescription
DIN 02099683: Pentasa
Raw flags: sec3=Y
Item: 564000049; group id 672; item number 1668; lccId None; manufacturer id FEI
Source form: Del-Release Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7770; ministry $0.7770
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02099683
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16855
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02099683
Shortage record checked October 6, 2026
Salofalk · DIN 02112787 · 500 mg · enteric-coated tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112787
Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2024-01-23 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 500 MG · company Abbvie corporation · schedule Prescription
DIN 02112787: Salofalk
Raw flags: sec3=Y
Item: 564000045; group id 672; item number 1674; lccId None; manufacturer id BFI
Source form: Ent Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.7685; ministry $0.7685
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02112787
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18214
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02112787
Shortage record checked October 6, 2026
Salofalk · DIN 02112760 · 500 mg · suppository
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112760
Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2024-07-10 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 500 MG · company Abbvie corporation · schedule Prescription
DIN 02112760: Salofalk
Raw flags: sec3=Y
Item: 564000039; group id 672; item number 1678; lccId None; manufacturer id BFI
Source form: Sup; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.8896; ministry $1.8896
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02112760
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18212
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02112760
Shortage record checked October 6, 2026
Salofalk · DIN 02242146 · 1000 mg · suppository
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Salofalk · DIN 02242146
Manufacturer: Axcan Pharma Inc.; listing date 2005-09-27
Health Canada: Marketed since 2024-03-28 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1000 MG · company Abbvie corporation · schedule Prescription
DIN 02242146: Salofalk
Raw flags: sec3=Y
Item: 564000100; group id 672; item number 1680; lccId None; manufacturer id BFI
Source form: Sup; strength: 1000mg
Recorded listing: General benefit
Source prices (unrounded): $2.7754; ministry $1.4005
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242146
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65824Interchangeable products
ZDS-Mesalamine Suppositories · DIN 02562367 · $1.4005
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242146
Shortage record checked October 6, 2026
ZDS-Mesalamine Suppositories · DIN 02562367 · 1000 mg · suppository
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
ZDS-Mesalamine Suppositories · DIN 02562367
Manufacturer: Zydus; listing date 2026-05-29
Health Canada: Marketed since 2026-03-11 · brand ZDS-MESALAMINE SUPPOSITORIES · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1000 MG · company Zydus lifesciences limited · schedule Prescription
ZDS-Mesalamine Suppositories: Formulary list price $1.40 per unit (the source does not state the unit; exact figure $1.4005). What the ministry pays, not the patient.
Ministry pays: $1.4005 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02562367: ZDS-Mesalamine Suppositories
Raw flags: sec3=Y
Item: 564000100; group id 672; item number 1680; lccId None; manufacturer id ZDS
Source form: Sup; strength: 1000mg
Recorded listing: General benefit
Source prices (unrounded): $1.4005; ministry $1.4005
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562367
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106525Interchangeable products
Salofalk · DIN 02242146 · $1.4005
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02562367
Shortage record checked October 6, 2026
Asacol · DIN 01997580 · 400 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.Discontinued July 17, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Asacol · DIN 01997580
Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01
Health Canada: Cancelled post market since 2020-07-17 · brand ASACOL · ATC A07EC02 MESALAZINE · form Tablet (enteric-coated) · route Oral · ingredients MESALAZINE 400 MG · company Allergan inc · schedule Prescription
DIN 01997580: Asacol
Raw flags: notABenefit=Y, sec3=Y
Item: 564000030; group id 672; item number 1681; lccId None; manufacturer id WAR
Source form: Tab; strength: 400mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01997580
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14552Interchangeable products
Teva-5-ASA · DIN 02171929 · $0.4758
Shortage status: discontinued (July 24, 2020, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01997580
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 17, 2020 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (A07E, A07EC): coverage varies; not interchangeable
Mesalazine (Octasa): general benefit
Olsalazine (Dipentum): general benefit
Budesonide (Uceris): general benefit
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered
Matched class: 56:40 Miscellaneous G.I. Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE
Some products covered without a code (check the product listing): CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL
56:40 Miscellaneous G.I. Drugs
· 16 products · General benefit · strengths: 10mg, 20mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40
and 10 more
1. Indications
PENTASA (mesalazine) extended-release tablets are indicated for:
• Treatment of mild to moderate active ulcerative colitis and for long-term maintenance
therapy in order to maintain remission and prevent relapse of active disease.
• Management of mild to moderate Crohn’s Disease and maintenance of Crohn’s Disease
in remission induced by surgery or medication
PENTASA (mesalazine) rectal suspension is indicated for:
• Treatment of acute distal ulcerative colitis extending to the splenic flexure and for long-term
maintenance therapy in order to maintain remission and prevent relapse of active disease.
Clinical experience has shown that topical PENTASA (i.e. enemas/suppositories) is superior to
oral PENTASA (i.e. tablets) with regard to therapeutic efficacy in distal ulcerative colitis (Table
3 - Clinical experience from pivotal trials).
PENTASA (mesalazine) suppositories are indicated for:
• Treatment of acute ulcerative proctitis and for long-term maintenance therapy in order to
maintain remission and prevent relapse of a…
https://pdf.hres.ca/dpd_pm/00084316.PDF
PM date: 2026-04-16
Source product: PENTASA; DIN 02099683; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Salofalk · DIN 02112809
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02112809
Salofalk · DIN 02112760
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02112760
Salofalk · DIN 02242146
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242146
Asacol · DIN 01997580
Shortage status: discontinued (2020-07-24, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01997580
For Asacol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.